Company Overview and News

 
STRATA Skin Sciences to Participate in Panel Discussion at The MedTech Conference

2018-09-17 globenewswire
HORSHAM, Pa., Sept. 17, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will participate in a panel discussion, titled “Alternative to the Exit: Start-ups building long-term value” at The MedTech Conference at the Pennsylvania Convention Center in Philadelphia on Monday, September 24th at 8:30 am Eastern Time.
MELA SSKN

21
Week 38 Breakout Forecast: Short-Term Picks To Give You An Edge

2018-09-17 seekingalpha - 4
Publishing two of the eight new Week 38 breakout stocks that are available only to subscribers, with better than 10% short-term upside potential.
ADAP EVC CGEN SW SSKN MEIP SWIR CDMO MELA MNOV CMCM PXLW GOGO

3
Strata Skin Sciences: Will This Be A Successful Turnaround In The Making?

2018-09-07 seekingalpha - 3
The management is streamlining with the appointment of the interim CEO (Dr. Dolev Rafaeli) is prudent.
MELA SSKN

 
STRATA Skin Sciences to Participate in H.C. Wainwright’s 20th Annual Global Investment Conference

2018-08-27 globenewswire
HORSHAM, Pa., Aug. 27, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the H. C.
MELA SSKN

 
STRATA Skin Sciences Announces Strategic Agreement with a Large Private Equity Backed Group of Dermatology Clinics

2018-08-20 globenewswire
Agreement will add to group’s business offering and enhance the individual clinics’ abilities to offer proven and cost-effective treatments to psoriasis, vitiligo and atopic dermatitis patients
MELA SSKN

 
STRATA Skin Sciences, Inc. (SSKN) CEO Dr. Dolev Rafaeli on Q2 2018 Results - Earnings Call Transcript

2018-08-13 seekingalpha
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q2 2018 Results Earnings Conference Call August 13, 2018 4:30 PM ET
MELA SSKN

30
Your Daily Pharma Scoop: Foundation Promising, Paratek Moves Up, Ovid Down

2018-08-08 seekingalpha - 2
Discussion: Foundation Medicine’s (FMI) announced a positive outcome of its bTMB assay. In a recent publication in Nature Medicine, a retrospective analysis of more than one thousand samples from NSCLC patients who participated in Roche (OTCQX:RHHBY) Genetech’s trials showed that use of Foundation Medicine’s (FMI) blood tumor mutational burden (‘bTMB) assay would have helped predict responses to TECENTRIQ (atezolizumab).
INO GILD PRTK TEVA OVID TEVVF ELTP SSKN PTIE MELA TEVJF EIGR PTGX FMI PFE

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to MELA / MELA Sciences, Inc on message board site Silicon Investor.

MELA Sciences MELA Sciences MELA Sciences Valley Forge Composite Technologies Inc. (VLYF.OB) Homeland Valley Forge Composite Technologies Inc. (VLYF.OB) Homeland Valley Forge Composite Technologies Inc. (VLYF.OB) Homeland
HSCC - Homeland Security Corp HSCC - Homeland Security Corp HSCC - Homeland Security Corp DEPARTMENT OF HOMELAND STUPIDITY DEPARTMENT OF HOMELAND STUPIDITY DEPARTMENT OF HOMELAND STUPIDITY
Homeland Security Homeland Security Homeland Security HISC -- Homeland Integrated Security Systems Inc. HISC -- Homeland Integrated Security Systems Inc. HISC -- Homeland Integrated Security Systems Inc.
Carmela Soprano Should Get Whacked Next! Carmela Soprano Should Get Whacked Next! Carmela Soprano Should Get Whacked Next! HOMELAND SECURITY TECH HOMELAND SECURITY TECH HOMELAND SECURITY TECH
HSYN -- Homeland Security Network, Inc. HSYN -- Homeland Security Network, Inc. HSYN -- Homeland Security Network, Inc. Homeland Security Homeland Security Homeland Security
CUSIP: 86272A107